Hepatomegaly

Phase 3 trials (2)

• octreotide
• lanreotide

Phase 2 trials (3)

• nivolumab
• ruxolitinib
• Isatuximab

Other trials (2)

• ursodeoxycholic acid
• s-adenosyl methionine

Organization Involved with Phase 3 Indications (6)

• Ipsen
• Novartis
• National Center for Research Resources (NCRR)
• Katholieke Universiteit Leuven
• Radboud University
• Mayo Clinic

Organization Involved with Phase 2 Indications (5)

• Incyte
• National Cancer Institute (NCI)
• Southwest Oncology Group
• Stanford University
• University of Texas at Houston